| Literature DB >> 25165407 |
L Massaccesi1, G V Melzi d'Eril2, G M Colpi3, G Tettamanti4, G Goi1, A Barassi2.
Abstract
Oxidative stress (OS) and production of NO, by endothelium nitric oxide synthetase (eNOS), are involved in the pathophysiology of erectile dysfunction (ED). Moreover, OS induces modifications of the physicochemical properties of erythrocyte (RBC) plasma membranes and of the enzyme content of the same membranes. Due to their role in signalling early membrane alterations in OS-related pathologies, several plasma membrane and cytosolic glycohydrolases of human RBC have been proposed as new markers of cellular OS. In RBC, NOS can be activated and deactivated by phosphorylation/glycosylation. In this regulatory mechanism O-β-N-AcetylGlucosaminidase is a key enzyme. Cellular levels of O-GlcNAcylated proteins are related to OS; consequently dysfunctional eNOS O-GlcNAcylation seems to have a crucial role in ED. To elucidate the possible association between RBC glycohydrolases and OS, plasma hydroperoxides and antioxidant total defenses (Lag-time), cytosolic O-β-N-AcetylGlucosaminidase, cytosolic and membrane Hexosaminidase, membrane β-D-Glucuronidase, and α-D-Glucosidase have been studied in 39 ED patients and 30 controls. In ED subjects hydroperoxides and plasma membrane glycohydrolases activities are significantly increased whereas Lag-time values and cytosolic glycohydrolases activities are significantly decreased. These data confirm the strong OS status in ED patients, the role of the studied glycohydrolases as early OS biomarker and suggest their possible use as specific marker of ED patients, particularly in those undergoing nutritional/pharmacological antioxidant therapy.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25165407 PMCID: PMC4137692 DOI: 10.1155/2014/485917
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Clinical and metabolic parameters of controls and ED patients.
| Controls | ED patients | Reference ranges | |
|---|---|---|---|
| Age, years | 50.1 ± 16.6 | 52.9 ± 10.6 | |
| Glycated hemoglobin | 5.0 ± 0.4 | 5.1 ± 0.4 | ≤6.5 (%) |
| Total cholesterol | 180 ± 18 | 175 ± 16 | <200 (mg/dL) |
| HDL cholesterol | 42 ± 9 | 49 ± 10 | >35 (mg/dL) |
| LDL cholesterol | 107 ± 15 | 117 ± 25 | <160 (mg/dL) |
| Triglycerides | 114 ± 31 | 115 ± 45 | <160 (mg/dL) |
| 17-beta estradiol | 38 ± 5 | 28 ± 8 | <60 (pg/mL) |
| Prolactin | 12 ± 4 | 9 ± 5 | 2–17 (ng/mL) |
| Testosterone | 5.1 ± 0.9 | 4.6 ± 2 | 3–10 (ng/mL) |
| LH | 6.9 ± 2.9 | 5.7 ± 2.3 | 1.3–13 (U/L) |
HDL: high-density lipoprotein; LDL: low-density lipoprotein; LH: luteinizing hormone.
Values are expressed as mean ± standard deviation (SD).
Figure 1Plasma peroxidation parameters. Hydroperoxides are expressed as equivalent of H2O2 mg/dL of plasma. ***P < 0.001 controls versus ED subjects.
Figure 2Erythrocyte membrane anisotropy and membrane-bound glycohydrolases activities. DPH: Diphenyl-1,3,5-hexatriene. TMA-DPH: 1-[4-(trimethyl-amino)-phenyl]-6-phenyl-1,3,5-hexatriene. **P < 0.01 and ***P < 0.001 controls versus ED subjects.
Figure 3Glycohydrolases activities in the erythrocyte cytosol. **P < 0.01 and ***P < 0.001 controls versus ED subjects.